CFD’er er komplekse instrumenter, og der er en stor risiko forbundet med disse for at miste penge på grund af gearing. 74.2 % af detailinvestorerne har tab på deres konto, når de handler CFD’er med denne udbyder.Du skal overveje, om du forstår, hvordan CFD’er fungerer, og om du har råd til at løbe en stor risiko for at miste dine penge.

Close

Handel Gilead GILD

Sælge
 Køb

Gilead live diagram

5m 15m 30m 1h 4h 1d 1w

Grundlæggende Instrumenter

Weekly Search
Weekly
Daily
Dato Luk Ændring % Ændre Åbn Høj Lav

Seneste nyheder

Frances Wang 2025 Mar 17, 16:00

Stock market today: Dow, S&P 500, Nasdaq remain steady on tariff tension

Stocks Indices
Frances Wang 2025 Mar 16, 16:00

Stock market index update: Hang Seng Index rises over 1.11%

Indices
Frances Wang 2025 Mar 16, 16:00

Oil Market Today: Oil prices surge amid rising tensions in the Red Sea

CFD Trading Oil Commodities
Tommy Yap 2025 Mar 16, 16:00

Morning Note: U.S. Retail Data, XRP Whale Activity, and Euro Gains

Morning Note USD Cryptocurrencies Forex
Tommy Yap 2025 Mar 15, 16:00

Week Ahead: BoJ, Fed, SNB, and BoE: How Will They Shape the Market?

Forex Indices
Frances Wang 2025 Mar 13, 16:00

Bank of Japan to discuss economic risks associated with the Trump trade war

Fed BoJ
Frances Wang 2025 Mar 13, 16:00

Dow Jones futures decline following a Nasdaq rally led by Tesla and Nvidia

Indices
Tommy Yap 2025 Mar 13, 16:00

Morning Note: UK GDP Data, NVDA Stock Dip, & CAD Weakness Amid Oil Decline

Morning Note NVDA Forex Oil

Info

Spread

0.75

Spread (%)

0.6832 %

Gearing

1:5

Dag til dag-rente Køb

-0.0597 %

Dag til dag-rente Sælg

-0.0292 %

Valuta

USD

Åbningstider for handel

Market lukket

Onsdag

13:31 - 19:59

Mandag

13:31-19:59

Tirsdag

13:31-19:59

Torsdag

13:31-19:59

Fredag

13:31-19:59

Analyse og statistikker

Åbn

---

Forrige luk

---

52 uger høj/lav

--- – ---

Markedsværdi

139803000832

Aktier udestående

1245350016

Indtjeningsdato (Næste)

2013-01-28

Udbytteprocent

2025-03-28

Ex-udbyttedato

2025-03-14

Forventet årlig udbyttesats

3.16

Forventet årlig udbytteprocent

0.0284

EPS

0.38

Få mere at vide om dette instrument

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for virology, oncology and other therapeutic areas in the United States, Europe, and internationally. The company offers Biktarvy, Genvoya, Descovy, Odefsey, Complera/Eviplera, Symtuza, Truvada, Stribild, and Sunlenca products for the treatment of HIV-1 infection; Veklury, an injection for intravenous use for the treatment of COVID-19; and Epclusa, Vemlidy, Harvoni, Viread, and Livdelzi for the treatment of liver disease. It also provides Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. In addition, the company's portfolio of market products includes Atripla, Cayston, Descovy for PrEP, Emtriva, Hepcludex, Hepsera, Jyseleca, Sovaldi, Truvada for PrEP, Tybost, Vosevi, and Zydelig. It has collaboration agreements with Arcellx, Inc.; Merck & Co., Inc.; Arcus Biosciences, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Everest Medicines; Abingworth LLP; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Relaterede instrumenter

Aktiv
Sælge
Køb
% Ændre

Handl nu

Handl nu

Handl nu

Handl nu
Relaterede instrumenter
Trustpilot